BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 34,980 Shares of Stock

BridgeBio Pharma logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • BridgeBio CEO Neil Kumar sold 34,980 shares for about $2.72 million under a pre-arranged Rule 10b5-1 plan, reducing his direct stake by 12.57% to 243,327 shares.
  • BridgeBio shares fell 2.8% to $76.03 on Friday, though the price remained between its 52-week low of $62.50 and high of $93.42.
  • The company beat quarterly earnings and revenue estimates, with revenue up 192.6% year over year. Analysts’ consensus rating was “Moderate Buy,” with an average price target of $104.42.
  • MarketBeat previews the top five stocks to own by December 1st.

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 34,980 shares of the business's stock in a transaction dated Wednesday, November 18th. The stock was sold at an average price of $77.72, for a total transaction of $2,718,645.60. Following the completion of the transaction, the chief executive officer directly owned 243,327 shares in the company, valued at $18,911,374.44. This trade represents a 12.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Neil Kumar also recently made the following trade(s):

  • On Wednesday, November 18th, Neil Kumar sold 10,000 shares of BridgeBio Pharma stock. The shares were sold at an average price of $77.72, for a total transaction of $777,200.00.
  • On Thursday, September 17th, Neil Kumar sold 10,000 shares of BridgeBio Pharma stock. The stock was sold at an average price of $69.08, for a total transaction of $690,800.00.

BridgeBio Pharma Stock Down 2.8%

NASDAQ BBIO traded down $2.15 during trading hours on Friday, reaching $76.03. 1,478,712 shares of the company were exchanged, compared to its average volume of 2,889,236. BridgeBio Pharma, Inc. has a 1 year low of $62.50 and a 1 year high of $93.42. The business's 50 day simple moving average is $70.22 and its 200-day simple moving average is $72.78. The stock has a market capitalization of $14.81 billion, a P/E ratio of -25.01 and a beta of 0.97.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last released its earnings results on Thursday, October 29th. The company reported ($0.42) earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.12. The company had revenue of $353.17 million during the quarter, compared to analysts' expectations of $293.47 million. During the same quarter in the previous year, the firm earned ($0.95) earnings per share. The firm's revenue was up 192.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that BridgeBio Pharma, Inc. will post -2.55 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on the company. HC Wainwright reiterated a "buy" rating on shares of BridgeBio Pharma in a research note on Tuesday, October 6th. Wells Fargo & Company increased their price objective on BridgeBio Pharma from $98.00 to $102.00 and gave the company an "overweight" rating in a report on Tuesday, August 11th. JPMorgan Chase & Co. raised their target price on BridgeBio Pharma from $100.00 to $111.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 12th. Truist Financial boosted their target price on BridgeBio Pharma from $102.00 to $107.00 and gave the company a "buy" rating in a research note on Wednesday, August 12th. Finally, Citigroup dropped their price target on BridgeBio Pharma from $94.00 to $91.00 and set a "neutral" rating on the stock in a research report on Monday, October 19th. Nineteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $104.42.

Get Our Latest Report on BridgeBio Pharma

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Jupiter Topco LLC bought a new stake in BridgeBio Pharma during the 2nd quarter valued at $1,050,762,000. Janus Henderson Group PLC boosted its holdings in shares of BridgeBio Pharma by 19.8% in the first quarter. Janus Henderson Group PLC now owns 13,179,013 shares of the company's stock worth $978,608,000 after acquiring an additional 2,178,556 shares during the period. The Manufacturers Life Insurance Company bought a new position in shares of BridgeBio Pharma in the second quarter worth $145,663,000. Primecap Management Co. CA purchased a new position in shares of BridgeBio Pharma in the second quarter valued at $75,670,000. Finally, Groupama Asset Managment purchased a new position in shares of BridgeBio Pharma in the third quarter valued at $720,000. 99.85% of the stock is owned by institutional investors.

About BridgeBio Pharma

(Get Free Report)

BridgeBio Pharma is a biopharmaceutical company that discovers, develops and commercializes medicines for genetic diseases and cancers. Founded in 2015, the company advances programs through a network of research and development subsidiaries focused on specific conditions and therapeutic areas. Its products include Attruby (acoramidis), an FDA-approved treatment for adults with transthyretin amyloid cardiomyopathy. BridgeBio also develops a pipeline of investigational therapies aimed at diseases with well-understood genetic causes, including rare and inherited conditions.

Featured Articles

Insider Buying and Selling by Quarter for BridgeBio Pharma (NASDAQ:BBIO)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in BridgeBio Pharma Right Now?

Before you consider BridgeBio Pharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BridgeBio Pharma wasn't on the list.

While BridgeBio Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines